{"id":947236,"date":"2026-03-27T07:55:14","date_gmt":"2026-03-27T11:55:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/"},"modified":"2026-03-27T07:55:14","modified_gmt":"2026-03-27T11:55:14","slug":"profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/","title":{"rendered":"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO, March  27, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2sVO_sShLW1C8-p8jEb3KXUv3DvnplPd7ypkKd7MrjsGsHZBMcsKpp22PSDHArawcsnN7AsljjmWAouGepXtXIIviBM42hxVItURvbb1H-w=\" rel=\"nofollow\" target=\"_blank\">Profound Medical Corp.<\/a> (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RlUYk6tlzlGM8gIQJr9GV-Scoey2n-ulw0UzD6gnsw8XUE_kiLwUR3zCqoJAJ-lBNhX8cKY5-_7L6RjvmHOvciqBNqmtN1IRInAG_aM-iT0SOiE3UB0TVncOg0r-v30nvNc8NEYxwWio1w8t4X6OaQ==\" rel=\"nofollow\" target=\"_blank\">TULSA Procedure\u2122<\/a> performed in Dallas Medical Center\u2019s state-of-the-art MRI suite.<\/p>\n<p align=\"justify\">\u201cHaving performed hundreds of focal HIFU procedures for prostate cancer patients, we switched to primarily offering the TULSA Procedure because its unique MRI-guidance and thermography allow us to treat a much broader range of prostate diseases, sizes, severities, and aggressions, with an improved safety profile. With TULSA, by planning and delivering therapy under continuous, in\u2011bore MRI visualization \u2014 rather than relying on diagnostic images obtained weeks or months earlier and aligned indirectly at the time of treatment in the case of HIFU \u2014 we gain a clearer, more accurate understanding of tumor location and extent, enabling more precise and safer therapy,\u201d said Dr. Cochran. \u201cAlmost immediately upon transitioning from a private pay to a Medicare model via our new collaboration with Dallas Medical Center, our TULSA Procedure numbers increased by 500%, and continue to grow as new enquiries from around Texas and surrounding states come in every day, and urologists in the Dallas-Fort Worth Metroplex reach out to learn how to offer TULSA to their patients.\u201d<\/p>\n<p align=\"justify\">\u201cUnder this innovative model pioneered by Texas Prostate \u2014 bridging private-pay practices and Medicare-participating hospitals \u2014 Dr. Cochran is demonstrating a way for urologists to accelerate adoption of the next generation of prostate care by allowing more men to benefit from the TULSA Procedure\u2019s versatility across the full spectrum of prostate disease,\u201d commented Arun Menawat, Profound\u2019s CEO and Chairman. \u201cOn behalf of everyone at Profound, we would like to congratulate Dr. Cochran and his team on his first 100 TULSA Procedures.\u201d<\/p>\n<p align=\"justify\">The TULSA Procedure, performed using the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RlUYk6tlzlGM8gIQJr9GV9gYET35cG_WNTruEMkMlrV_Ar7L5MDzS64q0rnsku_KV6sPLE95RFidmOnSASVHEfIS74XRsmb2-p2aQ3qAZbs=\" rel=\"nofollow\" target=\"_blank\">TULSA-PRO<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lY13rbvHoDGGvjq3eNL4WmkYBQ031rdAsfDBvlivbv3_FZOY2CQVwQ2KqkUnNOU6ADjDunoKrBBB8j7_ipAifzB3axi2g2qbLIYkuC6e9eM=\" rel=\"nofollow\" target=\"_blank\"><sup>\u00ae<\/sup><\/a> system, represents a major advancement in prostate care, and is used by physicians to treat men with prostate cancer and\/or benign prostatic hyperplasia (\u201cBPH\u201d, also known as an enlarged prostate). Robotically controlled directional ultrasound is delivered from inside the urethra to precisely and gently heat prostate tissue to \u2018kill temperature\u2019 (55-57\u00b0C), while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure. This level of precision allows physicians to tailor therapy to each patient, resulting in no procedural blood loss, no overnight hospital stay, and a quicker return to everyday life, while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and\/or erectile dysfunction.<\/p>\n<p align=\"justify\">\n        <strong>About Profound Medical Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control, and patient outcomes. By leveraging real-time MRI guidance, Profound\u2019s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.<\/p>\n<p align=\"justify\">The company\u2019s flagship platform, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RlUYk6tlzlGM8gIQJr9GV9A29-ux_FDkoPEv4nWON2OFeuuIlUZehUcIXkNqBa4TGoaTli6CUYQYjZCQdenjIdCS1apzoJisR8ZPTOkT7F0=\" rel=\"nofollow\" target=\"_blank\">TULSA-PRO<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rMNylb2mfi7oUTh7TkH-RszuIxqLeYfwA7uJtHiALf5rCZ6XEjx3CBJRu3av1KmqvZvONM-KXfHiw_6KicYsFrCJIMGIM4RUWnBHbtSxrpo=\" rel=\"nofollow\" target=\"_blank\"><sup>\u00ae<\/sup><\/a>, enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RlUYk6tlzlGM8gIQJr9GVw95Eq0soEt_tQEKDrWygQHTc-JZwnE3Ou1M1Ti5tSVZw2QUeyeDHlBkn45UgA98o-9yqDU2DLMLAX3dIqRHUTEp-T6yENjE7jMlyh_DIX6M2GgeevtHoZTV-9-kDYb2lA==\" rel=\"nofollow\" target=\"_blank\">TULSA Procedure\u2122<\/a> allows physicians to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care \u2014 from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and\/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and\/or erectile dysfunction.<\/p>\n<p align=\"justify\">Profound also commercializes <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LOt56jN0pXAFix-ZD_4KV080t4J6ePtkoQDvDh8oLd-Jlmx981JPDAr_F7DNHieMa4G9yngPcRo1_kjj0WNmC4pOxs2PVitS32ATKGK0Fao=\" rel=\"nofollow\" target=\"_blank\">Sonalleve<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GiGmfcssaMslztWVKeAQBwR7UEg-GGqvbuCSW9EmaBnc_JbtamB9omSFjgw4qn-H8xz-K6aLhCbUFN-F-6GSqYjk_TaLfODb3aeQ0vBGsuo=\" rel=\"nofollow\" target=\"_blank\"><sup>\u00ae<\/sup><\/a>, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery \u2014 and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.<\/p>\n<p align=\"justify\">Profound Medical\u2019s technologies are approved across major global markets. TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia\/New Zealand, and the UAE, while Sonalleve is cleared or approved in the United States (HDE), Europe, Canada, China, and Saudi Arabia.<\/p>\n<p align=\"justify\">Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy \u2014 expanding access to precise, personalized, and incision-free treatment options worldwide.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the safety and efficacy of Profound\u2019s technology in the treatment of prostate cancer, BPH, pain palliation of bone metastases, desmoid tumors, osteoid osteoma, uterine fibroids and adenomyosis. Often, but not always, forward-looking statements can be identified by the use of words such as &#8220;plans&#8221;, &#8220;is expected&#8221;, &#8220;expects&#8221;, &#8220;scheduled&#8221;, &#8220;intends&#8221;, &#8220;contemplates&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;proposes&#8221; or variations (including negative variations) of such words and phrases, or state that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221; or &#8220;will&#8221; be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound&#8217;s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9TCmwXhDwijtmv7wBb_1302I-hJEdzisgOEHLYjPj6D5iTgXIFNQVWjGx-wY5gFtokyXmEMC9bBDAPw4jxn3jl_VFSQAn8PGTxsyG43da50=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.com<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9TCmwXhDwijtmv7wBb_13yMwhjVyueHriRO0b5I6oEBfYRG_Z4C0J2k5YJtFXxPuEUHeZshZEHuvSoaDT3NZpQ==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Stephen Kilmer<br \/>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MaHryf1FAAQPCYjn8wT2OJFR2l1-pxUt121ZkT1vXf8OeMwp3iwCPTh5V2mk52PVeJFCUyPq60mIBcQ9rqPhjVi8gexnYDKLo3_n1aAzMqY6TD17QUL7BNYPhBWNkw7m\" rel=\"nofollow\" target=\"_blank\">skilmer@profoundmedical.com<\/a><br \/>T: 647.872.4849<\/p>\n<p align=\"justify\">Susan Thomas<br \/>Public Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aT5YCVjSYaizJYUh5hQ6vmB-kgJLfqw8loIo8GcpFXUGvZdhEzefTITVVyX7tVI5MJu_iO3HOHfac09dSnET2PIrPO5ByTWpTO6GkRN60zsP_yqUs69JnZSLCgPrZrIF\" rel=\"nofollow\" target=\"_blank\">sthomas@profoundmedical.com<\/a><br \/>T: 619.540.9195<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjQ2NzYxOWMtYTI4Ni00NGU4LTlmMWMtYWY2Zjg2NjI2MmVlLTEwMzAxMTktMjAyNi0wMy0yNy1lbg==\/tiny\/Profound-Medical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO, March 27, 2026 (GLOBE NEWSWIRE) &#8212; Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure\u2122 performed in Dallas Medical Center\u2019s state-of-the-art MRI suite. \u201cHaving performed hundreds of focal HIFU procedures for prostate cancer patients, we switched to primarily offering the TULSA Procedure because its unique MRI-guidance and thermography allow us to treat a much broader range of prostate diseases, sizes, severities, and aggressions, with an improved safety profile. With TULSA, by planning and delivering therapy under continuous, in\u2011bore MRI visualization \u2014 rather &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-947236","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO, March 27, 2026 (GLOBE NEWSWIRE) &#8212; Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure\u2122 performed in Dallas Medical Center\u2019s state-of-the-art MRI suite. \u201cHaving performed hundreds of focal HIFU procedures for prostate cancer patients, we switched to primarily offering the TULSA Procedure because its unique MRI-guidance and thermography allow us to treat a much broader range of prostate diseases, sizes, severities, and aggressions, with an improved safety profile. With TULSA, by planning and delivering therapy under continuous, in\u2011bore MRI visualization \u2014 rather &hellip; Continue reading &quot;Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-27T11:55:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone\",\"datePublished\":\"2026-03-27T11:55:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/\"},\"wordCount\":1090,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/\",\"name\":\"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=\",\"datePublished\":\"2026-03-27T11:55:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/","og_locale":"en_US","og_type":"article","og_title":"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone - Market Newsdesk","og_description":"TORONTO, March 27, 2026 (GLOBE NEWSWIRE) &#8212; Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure\u2122 performed in Dallas Medical Center\u2019s state-of-the-art MRI suite. \u201cHaving performed hundreds of focal HIFU procedures for prostate cancer patients, we switched to primarily offering the TULSA Procedure because its unique MRI-guidance and thermography allow us to treat a much broader range of prostate diseases, sizes, severities, and aggressions, with an improved safety profile. With TULSA, by planning and delivering therapy under continuous, in\u2011bore MRI visualization \u2014 rather &hellip; Continue reading \"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-27T11:55:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone","datePublished":"2026-03-27T11:55:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/"},"wordCount":1090,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/","name":"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=","datePublished":"2026-03-27T11:55:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTY5OCM3NTA2OTY2IzIwMTg1NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-procedure-milestone\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure\u2122 Milestone"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=947236"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947236\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=947236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=947236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=947236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}